Shield Therapeutics (STX) Given Under Review Rating at Liberum Capital

Liberum Capital reissued their under review rating on shares of Shield Therapeutics (LON:STX) in a report released on Friday.

Separately, Peel Hunt reissued an under review rating on shares of Shield Therapeutics in a report on Thursday, February 22nd.

How to Become a New Pot Stock Millionaire

Shares of LON STX traded up GBX 4 ($0.06) during trading hours on Friday, reaching GBX 19.50 ($0.27). 265,219 shares of the stock traded hands, compared to its average volume of 48,665. Shield Therapeutics has a 52-week low of GBX 15 ($0.21) and a 52-week high of GBX 168.50 ($2.37).

WARNING: “Shield Therapeutics (STX) Given Under Review Rating at Liberum Capital” was published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this piece of content on another site, it was copied illegally and republished in violation of U.S. and international copyright and trademark legislation. The original version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/04/07/shield-therapeutics-stx-given-under-review-rating-at-liberum-capital.html.

About Shield Therapeutics

Shield Therapeutics plc, a specialty pharmaceutical company, focuses on the development and commercialization of secondary care-focused pharmaceuticals. Its lead product is Feraccru, a novel therapy for the treatment of iron deficiency anemia in patients with inflammatory bowel disease. Its advanced pipeline asset is PT20, a novel therapy that has completed its first pivotal study for the treatment of hyperphosphatemia in patients with chronic kidney disease.

Receive News & Ratings for Shield Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shield Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply